Alcon raises STAAR acquisition price to $30.75 per share

Alcon Inc. (SIX/NYSE: ALC) announced it has entered into an amended merger agreement to acquire STAAR Surgical Company (NASDAQ: STAA) for $30.75 per share in cash, an increase from the previously announced price.

The revised purchase price represents approximately $150 million in additional equity value for STAAR stockholders, bringing the total transaction value to approximately $1.6 billion. The new price represents a 74% premium to STAAR's 90-day Volume Weighted Average Price and a 66% premium to the closing price on August 4, 2025.

The amendment follows the completion of STAAR's "go-shop" period, which expired on December 6 without receiving any superior proposals. During this period, Alcon waived its matching rights and any break-up fee if a competing offer materialized.

Both companies' boards of directors have approved the amended merger agreement, and STAAR's board recommends stockholder approval. STAAR stockholders will vote on the transaction at a meeting scheduled for December 19, 2025.

Alcon plans to finance the acquisition through short- and long-term credit facilities. The company expects the transaction to be accretive to earnings in year two and anticipates closing in early 2026, subject to regulatory approvals and STAAR stockholder approval.

"The amended transaction provides tremendous value to STAAR stockholders, while providing an exciting opportunity for Alcon to broaden the access to STAAR's leading technology to benefit patients around the world," said David Endicott, Alcon's Chief Executive Officer.

STAAR specializes in phakic intraocular lenses, particularly its EVO family of Implantable Collamer Lenses for vision correction. The acquisition would expand Alcon's eye care portfolio beyond its current surgical and vision care products.

You May Also Be Interested In